Cover Image

The prognosis of anti-angiogenesis treatments combined with standard therapy for newly diagnosed glioblastoma: a meta-analysis of randomized controlled trials

Background and Purpose Although bevacizumab (BV) has been approved as second-line therapy for recurrent glioblastoma (GB), the efficacy and safety of BV for patients with newly diagnosed GB remain unclear. Methodology/Principal Findings We systematically searched electronic databases (PubMed, EMBASE...

Full description

Saved in:
Bibliographic Details
Main Authors: Li, Yuping (Author) , Hou, Mengzhuo (Author) , Lu, Guangyu (Author) , Ciccone, Natalia (Author) , Wang, Xingdong (Author) , Zhang, Hengzhu (Author)
Format: Article (Journal)
Language:English
Published: December 22, 2016
In: PLOS ONE
Year: 2016, Volume: 11, Issue: 12
ISSN:1932-6203
DOI:10.1371/journal.pone.0168264
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1371/journal.pone.0168264
Verlag, lizenzpflichtig, Volltext: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0168264
Get full text
Author Notes:Yuping Li, Mengzhuo Hou, Guangyu Lu, Natalia Ciccone, Xingdong Wang, Hengzhu Zhang

MARC

LEADER 00000caa a2200000 c 4500
001 169979572X
003 DE-627
005 20220818112515.0
007 cr uuu---uuuuu
008 200604s2016 xx |||||o 00| ||eng c
024 7 |a 10.1371/journal.pone.0168264  |2 doi 
035 |a (DE-627)169979572X 
035 |a (DE-599)KXP169979572X 
035 |a (OCoLC)1341328513 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Li, Yuping  |e VerfasserIn  |0 (DE-588)1167270800  |0 (DE-627)1030937885  |0 (DE-576)511071604  |4 aut 
245 1 4 |a The prognosis of anti-angiogenesis treatments combined with standard therapy for newly diagnosed glioblastoma  |b a meta-analysis of randomized controlled trials  |c Yuping Li, Mengzhuo Hou, Guangyu Lu, Natalia Ciccone, Xingdong Wang, Hengzhu Zhang 
264 1 |c December 22, 2016 
300 |a 16 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 04.06.2020 
520 |a Background and Purpose Although bevacizumab (BV) has been approved as second-line therapy for recurrent glioblastoma (GB), the efficacy and safety of BV for patients with newly diagnosed GB remain unclear. Methodology/Principal Findings We systematically searched electronic databases (PubMed, EMBASE, OVID, etc.) to identify related studies published from January 1966 and August 2016. Eight randomized controlled trials including a total of 2,185 patients with GB were included. We found that the median progression-free survival (PFS) was higher in the BV group than in the standard therapy (ST) group (pooled hazard ratio, 0.73; 95%CI, 0.62-0.86; P = 0.0001). Compared with ST, BV improved the PFS rate at 6 months (OR 3.33, 95% CI 2.73-4.06, p<0.00001) and 12 months (OR 2.10, 95% CI 1.74-2.54, p<0.00001). There were no significant differences in median overall survival between the BV and ST groups (OR, 1.01; 95%CI, 0.83-1.23; P = 0.95). The BV group had higher survival rates at 6 months (OR, 1.41; 95% CI, 1.09-1.84; P = 0.01) and 12 months (OR, 1.23; 95% CI, 1.02-1.48; P = 0.03), but a low survival rate at the 36-month follow-up (OR, 0.57; 95% CI, 0.32-0.98; P = 0.04). For the incidence of adverse events, three adverse outcomes were found to be significantly different between BV and ST groups, including hypertension (8.37% vs. 1.62%, p<0.000001), proteinuria (7.65% vs. 0%, p<0.001), and fatigue (14.54% vs. 9.01%, p = 0.05). Conclusions/Significance Our study indicates that combination of BV with ST for newly diagnosed GB did not improve the median overall survival but result in longer median PFS, maintaining the quality of life and functional status. However, the long-term use of BV is associated with a higher incidence of adverse events and mortality. Study Registration This research was registered at PROSPERO. (Registration Number: CRD42016038247). 
650 4 |a Adverse events 
650 4 |a Cancer detection and diagnosis 
650 4 |a Cancer treatment 
650 4 |a Glioblastoma multiforme 
650 4 |a Hypertension 
650 4 |a Malignant tumors 
650 4 |a Meta-analysis 
650 4 |a Prognosis 
700 1 |a Hou, Mengzhuo  |e VerfasserIn  |4 aut 
700 1 |a Lu, Guangyu  |d 1986-  |e VerfasserIn  |0 (DE-588)1063046572  |0 (DE-627)809004186  |0 (DE-576)420384472  |4 aut 
700 1 |a Ciccone, Natalia  |e VerfasserIn  |4 aut 
700 1 |a Wang, Xingdong  |e VerfasserIn  |4 aut 
700 1 |a Zhang, Hengzhu  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t PLOS ONE  |d San Francisco, California, US : PLOS, 2006  |g 11(2016,12) Artikel-Nummer 0168264, 16 Seiten  |h Online-Ressource  |w (DE-627)523574592  |w (DE-600)2267670-3  |w (DE-576)281331979  |x 1932-6203  |7 nnas  |a The prognosis of anti-angiogenesis treatments combined with standard therapy for newly diagnosed glioblastoma a meta-analysis of randomized controlled trials 
773 1 8 |g volume:11  |g year:2016  |g number:12  |g extent:16  |a The prognosis of anti-angiogenesis treatments combined with standard therapy for newly diagnosed glioblastoma a meta-analysis of randomized controlled trials 
856 4 0 |u https://doi.org/10.1371/journal.pone.0168264  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0168264  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200604 
993 |a Article 
994 |a 2016 
998 |g 1063046572  |a Lu, Guangyu  |m 1063046572:Lu, Guangyu  |d 50000  |e 50000PL1063046572  |k 0/50000/  |p 3 
999 |a KXP-PPN169979572X  |e 3682581731 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Yuping Li, Mengzhuo Hou, Guangyu Lu, Natalia Ciccone, Xingdong Wang, Hengzhu Zhang"]},"origin":[{"dateIssuedDisp":"December 22, 2016","dateIssuedKey":"2016"}],"id":{"doi":["10.1371/journal.pone.0168264"],"eki":["169979572X"]},"physDesc":[{"extent":"16 S."}],"relHost":[{"pubHistory":["1.2006 -"],"part":{"year":"2016","issue":"12","volume":"11","text":"11(2016,12) Artikel-Nummer 0168264, 16 Seiten","extent":"16"},"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"The prognosis of anti-angiogenesis treatments combined with standard therapy for newly diagnosed glioblastoma a meta-analysis of randomized controlled trialsPLOS ONE","note":["Schreibweise des Titels bis 2012: PLoS ONE","Gesehen am 20.03.19"],"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"Public Library of Science"}],"language":["eng"],"recId":"523574592","title":[{"title":"PLOS ONE","title_sort":"PLOS ONE"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisher":"PLOS ; PLoS","dateIssuedKey":"2006","dateIssuedDisp":"2006-","publisherPlace":"San Francisco, California, US ; Lawrence, Kan."}],"id":{"issn":["1932-6203"],"zdb":["2267670-3"],"eki":["523574592"]},"name":{"displayForm":["Public Library of Science"]}}],"person":[{"given":"Yuping","family":"Li","role":"aut","display":"Li, Yuping","roleDisplay":"VerfasserIn"},{"family":"Hou","given":"Mengzhuo","display":"Hou, Mengzhuo","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","display":"Lu, Guangyu","roleDisplay":"VerfasserIn","given":"Guangyu","family":"Lu"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Ciccone, Natalia","given":"Natalia","family":"Ciccone"},{"display":"Wang, Xingdong","roleDisplay":"VerfasserIn","role":"aut","family":"Wang","given":"Xingdong"},{"given":"Hengzhu","family":"Zhang","role":"aut","display":"Zhang, Hengzhu","roleDisplay":"VerfasserIn"}],"title":[{"title_sort":"prognosis of anti-angiogenesis treatments combined with standard therapy for newly diagnosed glioblastoma","title":"The prognosis of anti-angiogenesis treatments combined with standard therapy for newly diagnosed glioblastoma","subtitle":"a meta-analysis of randomized controlled trials"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 04.06.2020"],"language":["eng"],"recId":"169979572X"} 
SRT |a LIYUPINGHOPROGNOSISO2220 

Similar Items